No Data
US Stock MarketDetailed Quotes
MLYS Mineralys Therapeutics
Watchlist
6.530
-0.270-3.97% Close 12/06 16:00 ET
6.970High6.510Low93.21KVolume
6.970Open6.800Pre Close621.41KTurnover0.66%Turnover RatioLossP/E (TTM)268.42MMarket Cap21.98052wk HighLossP/E (Static)41.11MShares5.85052wk Low1.02P/B91.84MFloat Cap21.980Historical High--Dividend TTM14.06MShs Float5.850Historical Low--Div YieldTTM6.77%Amplitude6.666Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Mineralys Therapeutics Company
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
News
Mineralys Therapeutics(MLYS.US) Officer Buys US$25,355.93 in Common Stocks
$Mineralys Therapeutics(MLYS.US)$ Officer Congleton Jon purchased 4,250 shares of Common Stocks on Nov 22, 2023 at an average price of $5.9661 for a total value of $25,355.93.Source: Announcement What
Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript